0
variable(s) selected download| Category | Variable name | variable label (+ explanatory notes) | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient data | gebdat | Date of birth | ||||||||||||||||||||||||||||
| Patient data | gesl | Sex |
valuelist
+
|
|||||||||||||||||||||||||||
| Patient data | iacr | Counts following IACR rules for reporting incidence |
valuelist
+
|
|||||||||||||||||||||||||||
| Patient data | incdat | Incidence date
+
The incidence date is the date of the first histological or cytological confirmation of the tumour. It cannot be later than the start of treatment. If treatment begins before histological confirmation, the incidence date is the date of clinical diagnosis. It must always fall within three months of the first clinical visit related to this tumour.
|
||||||||||||||||||||||||||||
| Patient data | incjr | Year of incidence
+
The incidence date is the date of the first histological or cytological confirmation of the tumour. It cannot be later than the start of treatment. If treatment begins before histological confirmation, the incidence date is the date of clinical diagnosis. It must always fall within three months of the first clinical visit related to this tumour.
|
||||||||||||||||||||||||||||
| Patient data | ink_ses | Median income in postal code area as a proxy for socioeconomic status (SES)
+
Available from 2010. Socioeconomic status (SES) reflects an individual's social position, which strongly influences health and is linked to life expectancy in good health. Research on SES and health typically uses indicators such as education, income, occupation, and material wealth. This variable uses income as a proxy for SES.
Income data by postal code area were obtained from Statistics Netherlands (CBS), with 2019 as the reference year, downloaded on 16 October 2023 via https://www.cbs.nl/nl-nl/dossier/nederland-regionaal/geografische-data
/gegevens-per-postcode.
Income is defined as the median disposable household income, adjusted for household size and composition. For each area, the median standardised household income was compared to the national distribution and classified into one of five groups: low, lower-middle, middle, upper-middle, or high. Income thresholds (in euros) are available at: https://www.cbs.nl/nl-nl/longread/diversen/2023/statistische-gegevens-per-vierkant-en-postcode-2022-2021-2020-2019/4-beschrijving-cijfers. Because postal code areas often have few households, CBS also
considered the 99% confidence interval of the median income. If this interval spans multiple groups, a new category was created to reflect the range (e.g., 'low to lower-middle'). Categories may partially overlap due to this approach. If the median income is based on fewer than 10 households, it is classified as 'unclassifiable'. CBS originally defined 12 income categories.
For this variable, these were reduced to three to simplify analysis and remove overlaps.
Key considerations:
- Income is a snapshot and does not reflect accumulated wealth.
- Data are aggregated by postal code area, which may include substantial variation.
- Household income is strongly age-dependent; analyses should compare individuals within the same age group.
- Median disposable income is considered valid for up to 10 years before and after the reference year (2019).
|
valuelist
+
|
|||||||||||||||||||||||||||
| Patient data | leeft | Age at incidence date | ||||||||||||||||||||||||||||
| Patient data | mal | Previous or subsequent malignancies
+
Selection of malignancies to specify in the request:
-Period: Previous and/or subsequent malignancies, or based on a defined timeframe before or around the incidence date.
-Type: All cancer types in the NCR, or all malignant/invasive (excluding skin BCC), or a selection of specific tumour types.
NKR database content with full availability:
Period: Nationwide complete from 1989.
Exclusion criteria:
- Patients residing abroad at the time of incidence
- Basal cell carcinomas of skin and lip
- Second primary invasive and second non-invasive squamous cell carcinomas of the skin
- Adenocarcinoma in situ/high-grade dysplasia of colon, rectosigmoid and rectum
- Carcinoma in situ of the cervix
- Benign/borderline tumours, except: CNS tumours from 2001, Borderline ovarian tumours, AL amyloidosis from 2017, Polymorphic PTLD
|
valuelist
+
|
|||||||||||||||||||||||||||
| Patient data | mal_incdat | Incidence date of previous or subsequent malignancy | ||||||||||||||||||||||||||||
| Patient data | mal_int | Interval between incidence date and date of previous or subsequent malignancy | ||||||||||||||||||||||||||||
| Patient data | mal_tumsoort | Tumour type of previous or subsequent malignancy
+
Refers to the NCR tumour classification based on site, morphology, and behaviour. For more information, see: https://iknl.nl/nkr/registratie/tumorindeling
|
||||||||||||||||||||||||||||
| Patient data | meno_stat | Menopausal status at diagnosis
+
What is the menopausal status of the patient at the time of diagnosis. Information from the medical oncologist is preferred over information from the surgeon. Item available from 2011 up to and including 2019.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Patient data | ovldat | Date of death | ||||||||||||||||||||||||||||
| Patient data | post_cijf | Numeric part of the patient's postal code at the time of incidence | ||||||||||||||||||||||||||||
| Patient data | rook_stat | Smoking status
+
Available from 2020
|
valuelist
+
|
|||||||||||||||||||||||||||
| Patient data | vit_stat_dat | Date of vital status
+
Once a year, at the end of the first quarter, the NCR is linked to the Municipal Personal Records Database (GBA). The GBA is complete up to February of that year. Vital status reflects the status up to this date. For patients listed as alive in the GBA, the vital status date is the date up to which the GBA is complete. If a patient is recorded as deceased or emigrated, the vital status date is the date of death or emigration. Using this date and the incidence date, the interval between incidence and vital status (in days) is calculated.
|
||||||||||||||||||||||||||||
| Patient data | vit_stat_int | Interval between incidence date and date of vital status (days)
+
Once a year, at the end of the first quarter, the NCR is linked to the Municipal Personal Records Database (GBA). The GBA is complete up to February of that year. Vital status reflects the status up to this date. For patients listed as alive in the GBA, the vital status date is the date up to which the GBA is complete. If a patient is recorded as deceased or emigrated, the vital status date is the date of death or emigration. Using this date and the incidence date, the interval between incidence and vital status (in days) is calculated.
|
||||||||||||||||||||||||||||
| Patient data | vit_stat | Vital status
+
Once a year, at the end of the first quarter, the NCR is linked to the Municipal Personal Records Database (GBA). The GBA is complete up to February of that year. Vital status reflects the status up to this date. For patients listed as alive in the GBA, the vital status date is the date up to which the GBA is complete. If a patient is recorded as deceased or emigrated, the vital status date is the date of death or emigration. Using this date and the incidence date, the interval between incidence and vital status (in days) is calculated.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | topo | Topography excluding sublocation
+
Location of the primary tumour according to ICD-O-3.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | topo_sublok | Topography including sublocation
+
Location and sublocation of the primary tumour according to ICD-O-3.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | later | Laterality |
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | morf | Morphology
+
Histological type of the tumour (first four digits of the ICD-O morphology code) according to ICD-O-3.2.
|
valuelist
+
the table shows a selection of 12 values
|
|||||||||||||||||||||||||||
| Tumour data | gedrag | Behaviour
+
Tumour behaviour (fifth digit of the ICD-O morphology code).
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | diffgrad | (Differentiation) grade
+
Tumour differentiation grade (sixth digit of the ICD-O morphology code)
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | ct | cT (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | cn | cN (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | cm | cM (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | pt | pT (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | pn | pN (TNM)
+
The TNM classification uses the edition applicable at the time of incidence.
Meaning of the last character in pN:
S: Result based only on sentinel node examination (sn)
I: Isolated tumour cells (ITC)
M: Micrometastases (mi)
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | pm | pM (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | cstadium | Clinical TNM stage
+
cstadium: The clinical stage is based on cTNM, which is derived from information available before (neo-adjuvant) treatment, including findings during surgery (if not treated neo-adjuvantly) that influence the treatment plan.
Meaning of "X" (unknown): Stage cannot be calculated, e.g., TX/NX/M0. Meaning of "M" (missing): Indicates TNM not recorded, possibly due to incomplete registration or use of EoD staging instead of TNM. Meaning of "NVT" (not applicable): TNM staging does not apply to this tumour type for the given incidence period.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | pstadium | Pathological TNM stage
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
pstadium: The pathological (post-surgical) stage is based on pT, pN and pM. Also in case of pre-surgical therapy, pT and pN are used (ypT and ypN). When no tumour is detectable after pre-surgical therapy, this is shown as pstadium=0.
pM: Indicates whether there is pathological confirmation of distant metastases. There may be distant metastases that are not pathologically confirmed, which are therefore not included in the calculation for this variable.
Meaning of "X" (unknown): Stage cannot be calculated, e.g., TX/NX/M0.
Meaning of "M" (missing): Indicates TNM not recorded, possibly due to incomplete registration or use of EoD staging instead of TNM.
Meaning of "NVT" (not applicable): TNM staging does not apply to this tumour type for the given incidence period.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | stadium | TNM stage
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
Stadium: Based on pTNM supplemented by cTNM to best reflect the actual stage at diagnosis. Priority is given to pTNM values. If surgery did not occur, pTNM is unknown, or pre-surgical therapy was given (pTNM becomes ypTNM), cTNM values are used.
Meaning of "X" (unknown): Stage cannot be calculated, e.g., TX/NX/M0.
Meaning of "M" (missing): Indicates TNM not recorded, possibly due to incomplete registration or use of EoD staging instead of TNM.
Meaning of "NVT" (not applicable): TNM staging does not apply to this tumour type for the given incidence period.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | ceod | Clinical tumour extension (EoD)
+
The 'Extent of Disease' (EoD) staging is used for solid tumours where no standard staging system such as TNM exists. EoD staging was also used for morphology M8000 (no pathological confirmation) until incidence date 01-01-2012.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | peod | Pathological tumour extension (EoD)
+
The 'Extent of Disease' (EoD) staging is used for solid tumours where no standard staging system such as TNM exists. EoD staging was also used for morphology M8000 (no pathological confirmation) until incidence date 01-01-2012.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | ond_lymf | Number of regional lymph nodes examined
+
All lymph nodes examined as part of initial diagnostics and treatment combined.
|
||||||||||||||||||||||||||||
| Tumour data | pos_lymf | Number of positive regional lymph nodes | ||||||||||||||||||||||||||||
| Tumour data | diag_basis | Basis for diagnosis
+
Non-microscopic confirmation:
0 = death certificate only
1 = clinical examination only (medical history and physical)
2 = clinical diagnostic tests, exploratory surgery or autopsy (without microscopic confirmation)
4 = specific biochemical and/or immunological laboratory tests.
Microscopic confirmation:
5 = haematological (bone marrow cytology, e.g., bone marrow aspiration, blood smear) or cytological confirmation of primary tumour or metastases, or definite microscopic confirmation but unclear whether cytology or histology
6 = histological confirmation of metastases only, including at autopsy
7 = histological confirmation of primary tumour, or unclear whether histology refers to primary tumour or
metastasis, including autopsy with histology.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | birads | BI-RADS classification
+
Available between 2011 and 2020
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | dcis_comp | Presence of a DCIS component alongside the invasive tumour
+
Available since 2011.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | er_stat | Oestrogen receptor status
+
Available since 2005.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | er_waarde | Oestrogen receptor value
+
Available from 2005. Interpretation of ER and PR values depends on incidence date.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | her2_stat | HER2Neu receptor status
+
Available from 2005. HER2neu receptor status is based on immunohistochemistry supplemented with results from amplification tests (FISH/CISH/SISH).
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | her2_tech | Technique used for HER2/neu receptor assessment
+
Available between 2011 and 2019
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | mammaprint_uitslag | MammaPrint result
+
Available from 2011.
For patiënts with an incidence date after 1 August 2025, the MammaPrint result is reported in four categories (ultra-low risk, low risk, high risk 1, high risk 2). For the period 1 January 2011 to 1 August 2025, the MammaPrint result is available in two categories (low risk, high risk).
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | meta_incdat | Incidence date of metastasis | ||||||||||||||||||||||||||||
| Tumour data | meta_int | Interval between incidence date and date of metastasis (days)
+
The incidence date is defined as the date of the first histological or
cytological confirmation of the primary tumour.
The metastasis date refers to the first histological or cytological confirmation of the
metastasis. If histological confirmation does not occur within three
months, the clinical diagnosis date is used. Consequently, the
metastasis date may precede the primary tumour incidence date by up
to three months.
|
||||||||||||||||||||||||||||
| Tumour data | meta_topo_sublok | Topography including sublocation of metastasis
+
Metastasis location according to ICD-O-3. Metastatic sites have been recorded nationwide since 2008. For distant metastases at more than three sites, C768 was coded up to 2014 to indicate more than three locations. In 2017/2018 C768 may indicate more than four locations.
Explanation for records where both cM and pM show no metastases despite metastatic sites being recorded at diagnosis: cTNM is based on information available before (neo-adjuvant) treatment, including findings during surgery (if not treated neo-adjuvantly) that influence the treatment plan. pM indicates whether pathological
confirmation exists for distant metastases. If metastases are detected during or after neo-adjuvant treatment, TNM is not updated, but metastasis locations are recorded.
If the dataset includes metastasis locations after progression: only new or enlarged metastases are recorded, not all existing ones. C809 is coded for clinical progression when the site is unknown.
|
valuelist
+
the table shows a selection of 12 values
|
|||||||||||||||||||||||||||
| Tumour data | meta_topo | Topography excluding sublocation of metastasis
+
Metastasis location according to ICD-O-3. Metastatic sites have been recorded nationwide since 2008. For distant metastases at more than three sites, C768 was coded up to 2014 to indicate more than three locations. In 2017/2018 C768 may indicate more than four locations.
Explanation for records where both cM and pM show no metastases despite metastatic sites being recorded at diagnosis: cTNM is based on information available before (neo-adjuvant) treatment, including findings during surgery (if not treated neo-adjuvantly) that influence the treatment plan. pM indicates whether pathological
confirmation exists for distant metastases. If metastases are detected during or after neo-adjuvant treatment, TNM is not updated, but metastasis locations are recorded.
If the dataset includes metastasis locations after progression: only new or enlarged metastases are recorded, not all existing ones. C809 is coded for clinical progression when the site is unknown.
|
valuelist
+
the table shows a selection of 12 values
|
|||||||||||||||||||||||||||
| Tumour data | multifoc | Tumour multifocality |
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | oncotype_uitslag | Oncotype DX result
+
Available since 2011.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | palpabel | Tumour palpability
+
Item discontinued as of incidence date 1-1-2020.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | pr_stat | Progesterone receptor status
+
Available since 2005.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | pr_waarde | Progesterone receptor value
+
Available from 2005. Interpretation of ER and PR values depends on incidence date.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Tumour data | tum_afm | Pathological tumour size (mm)
+
Available since 2005.
|
||||||||||||||||||||||||||||
| Process data | bvo_detec | Tumour detected following referral from population-based screening
+
Available since 2011.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Process data | contact_zkh1 | Hospital of first contact regarding malignancy
+
The first hospital visited by the patient for symptoms related to the malignancy, and where, based on that visit, a (suspected) malignancy is determined.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Process data | diag_reden | Reason for diagnostic assessment
+
Available from 2019.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Process data | genmut_ond_dat | Date of genetic mutation testing | ||||||||||||||||||||||||||||
| Process data | genmut_ond_int | Interval incidence date and date of genetic mutation testing (days)
+
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||
| Process data | genmut_ond | Genetic mutation testing performed
+
Available from 2014
|
valuelist
+
|
|||||||||||||||||||||||||||
| Process data | lokalproc | Tumour localisation procedure
+
Available from 2013 up to and including 2023. Before 2018, recorded only for non-palpable tumours.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Process data | mari | MARI procedure performed
+
Available since 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Process data | mari_dat | Date of MARI procedure
+
Available since 2015.
|
||||||||||||||||||||||||||||
| Process data | mari_int | Interval incidence date and date of the MARI procedure (days)
+
Available since 2015. The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||
| Process data | mari_uitslag | Result of the MARI procedure
+
Available since 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Process data | mari_zkh | Hospital where the MARI procedure was performed
+
Available since 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Process data | mri | MRI scan performed
+
Available since 2011.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Process data | mri_dat | Date of MRI scan | ||||||||||||||||||||||||||||
| Process data | mri_int | Interval incidence date and date of MRI scan (days)
+
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||
| Process data | oksel_echo_dat | Date on which ultrasound-guided aspiration and/or biopsy of the axilla was performed | ||||||||||||||||||||||||||||
| Process data | oksel_echo | Ultrasound-guided aspiration and/or biopsy of the axilla performed
+
Available between 2014 and 2019
|
||||||||||||||||||||||||||||
| Process data | oksel_echo_int | Interval incidence date and date of ultrasound-guided aspiration and/or biopsy of the axilla (days) | ||||||||||||||||||||||||||||
| Process data | oksel_echo_uitslag | Result of ultrasound-guided aspiration and/or biopsy of the axilla
+
Available between 2014 and 2019
|
valuelist
+
|
|||||||||||||||||||||||||||
| Process data | oksel_echo_zkh | Hospital where ultrasound-guided aspiration and/or biopsy of the axilla was performed | ||||||||||||||||||||||||||||
| Process data | plast_chir_consult_dat | Date of first consultation with a plastic surgeon following ablation
+
Available from 2019.
|
||||||||||||||||||||||||||||
| Process data | plast_chir_consult_int | Interval incidence date and first consultation with a plastic surgeon following ablative surgery (days)
+
Available since 2019. The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||
| Process data | rt_consult_dat | Date of first consultation with a radiation oncologist for preoperative therapy
+
Available since 2011.
|
||||||||||||||||||||||||||||
| Process data | rt_consult_int | Interval incidence date and consultation with a radiotherapist for preoperative therapy (days)
+
Available since 2011.
|
||||||||||||||||||||||||||||
| Process data | swk | Sentinel lymph node procedure performed
+
Available regionally from 1998 and nationally from 2011.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Process data | swk_dat | Date of sentinel lymph node procedure | ||||||||||||||||||||||||||||
| Process data | swk_int | Interval incidence date and date of sentinel lymph node procedure (days)
+
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||
| Process data | swk_uitslag | Result of the sentinel lymph node procedure |
valuelist
+
|
|||||||||||||||||||||||||||
| Process data | swk_zkh | Hospital where the sentinel lymph node procedure was performed |
valuelist
+
|
|||||||||||||||||||||||||||
| Process data | zkh_patnum | Patient number in hospital | ||||||||||||||||||||||||||||
| Process data | zkh_consult_dat | Date of first hospital visit related to the malignancy
+
Available since 2015.
|
||||||||||||||||||||||||||||
| Process data | zkh2_consult_dat | Date of first consultation with treating physician at the second hospital
+
Available since 2011.
|
||||||||||||||||||||||||||||
| Process data | zkh2_consult_int | Interval incidence date and first consultation with a treating clinician at a second hospital (days)
+
Available since 2011.
|
||||||||||||||||||||||||||||
| Risk factors | chir_voor | History of breast surgery
+
Has previous surgery been performed on the breast where the current treatment takes place? Available from 2011.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Risk factors | gewicht | Patient weight (kg)
+
Available from 2020. Preferably, weight at surgery is recorded.
|
||||||||||||||||||||||||||||
| Risk factors | lengte | Patient height (cm)
+
Available from 2020.
|
||||||||||||||||||||||||||||
| Risk factors | perf_stat | WHO performance status before start of therapy
+
WHO performance status before starting therapy. If the Karnofsky score is noted in the medical record, it is converted to WHO score as described in Ma et al. 2010 - Interconversion of three measures of performance status: An empirical analysis. For breast cancer, performance status is recorded from 2011. The item is discontinued for breast cancer as of incidence date 1-1-2020.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Risk factors | zwanger | Pregnancy at diagnosis
+
Available from 2018
|
valuelist
+
|
|||||||||||||||||||||||||||
| Treatment data | basaal_okd_dat | Date of baseline axillary lymph node dissection
+
Available from 2016.
|
||||||||||||||||||||||||||||
| Treatment data | basaal_okd_int | Interval incidence date and date of baseline axillary lymph node dissection (days)
+
Available from 2016.
|
||||||||||||||||||||||||||||
| Treatment data | basaal_okd | Baseline axillary lymph node dissection performed
+
Available from 2016.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Treatment data | basaal_okd_zkh | Hospital where baseline axillary lymph node dissection was performed
+
Available from 2016.
|
||||||||||||||||||||||||||||
| Treatment data | chemo | Systemic chemotherapy classified as pre- or post-surgical
+
Determination of pre- and post-surgical therapy is based on the chronological order of procedures in the NCR. The first surgical resection is used as the reference point. Local surgical procedures (e.g. polypectomy, excision biopsy, TUR, photodynamic therapy, electrocautery, cryosurgery, radiofrequency ablation) are excluded from this determination.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Treatment data | chemo_code[1-n] | Code of systemic chemotherapy[1-n]
+
Systemic therapy drugs are recorded in the NCR using codes from the Anatomical Therapeutic Chemical classification system (ATC codes). Systemic therapy was not always recorded in detail; particularly before 2015, non-specific codes were used.
|
||||||||||||||||||||||||||||
| Treatment data | chemo_compl | Complications during or after systemic chemotherapy
+
Available between 2020 and 2022
|
||||||||||||||||||||||||||||
| Treatment data | chemo_start_int[1-n] | Interval incidence date and start date of systemic chemotherapy (days)[1-n]
+
The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||
| Treatment data | chemo_stop_int[1-n] | Interval incidence date and stop date of systemic chemotherapy (days)[1-n]
+
The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||
| Treatment data | chemo_startdat[1-n] | Start date of systemic chemotherapy[1-n] | ||||||||||||||||||||||||||||
| Treatment data | chemo_stopdat[1-n] | Stop date of systemic chemotherapy[1-n] | ||||||||||||||||||||||||||||
| Treatment data | chemo_zkh[1-n] | Hospital where systemic chemotherapy was administered[1-n] | ||||||||||||||||||||||||||||
| Treatment data | chir | Surgery performed
+
Defined as surgery directed at the breast. In addition, ALND is also considered surgery if it is the only resection for occult breast carcinoma (cT=0). Incidental findings during surgery for another indication do not count if a further surgical resection follows; these are then considered incidental findings at biopsy. Local tumour excision does not count if it is the only surgery; it is then considered an excision after previous amputation not directed at the tumour, and these patients are considered not operated on in analyses.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Treatment data | chir_compl | Complication during or after surgery
+
Available from 2020 onwards.
Indicates whether complications occurred during or after surgery.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Treatment data | chir_dat[1-2] | Date of surgery[1-2] | ||||||||||||||||||||||||||||
| Treatment data | chir_int[1-2] | Interval between incidence date and date of surgery (days)[1-2]
+
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||
| Treatment data | chir_opnameduur[1-2] | Length of hospital stay after surgery (days)[1-2] | ||||||||||||||||||||||||||||
| Treatment data | chir_toeval | Tumour was an incidental finding during surgery for another indication |
valuelist
+
|
|||||||||||||||||||||||||||
| Treatment data | chir_type[1-2] | Type of surgery[1-2]
+
Defined as surgery directed at the breast. In addition, ALND is also considered surgery if it is the only resection for occult breast carcinoma (cT=0). Incidental findings during surgery for another indication do not count if a further surgical resection follows; these are then considered incidental findings at biopsy. Local tumour excision does not count if it is the only surgery; it is then considered an excision after previous amputation not directed at the tumour, and these patients are considered not operated on in analyses.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Treatment data | chir_zkh[1-2] | Hospital where surgery was performed[1-2] |
valuelist
+
|
|||||||||||||||||||||||||||
| Treatment data | dcis_rad_laatste | Radicality of the DCIS component at last surgery
+
Available since 2011.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Treatment data | dcis_rad1 | Radicality of the DCIS component at initial surgery
+
Available since 2011.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Treatment data | dir_reconstr_dat | Date of immediate reconstruction | ||||||||||||||||||||||||||||
| Treatment data | dir_reconstr_int | Interval incidence date and date of immediate reconstruction (days)
+
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||
| Treatment data | dir_reconstr | Immediate reconstruction performed
+
Available from 2011. Direct reconstruction, or preparation for it (e.g. placement of a tissue expander), is recorded only if performed during mastectomy. This variable does not relate to oncoplastic reconstruction during lumpectomy.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Treatment data | dir_reconstr_tech | Technique of immediate reconstruction
+
Available from 2014. The meaning of the technique of direct reconstruction depends on the direct reconstruction code.
|
||||||||||||||||||||||||||||
| Treatment data | dir_reconstr_zkh | Hospital where immediate reconstruction was performed | ||||||||||||||||||||||||||||
| Treatment data | geen_rt_reden | Reason for no radiotherapy after breast-conserving surgery
+
Available from 2018
|
valuelist
+
|
|||||||||||||||||||||||||||
| Treatment data | horm | Systemic hormonal therapy classified as pre- or post-surgical
+
Determination of pre- and post-surgical therapy is based on the chronological order of procedures in the NCR. The first surgical resection is used as the reference point. Local surgical procedures (e.g. polypectomy, excision biopsy, TUR, photodynamic therapy, electrocautery, cryosurgery, radiofrequency ablation)are excluded from this determination.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Treatment data | horm_code[1-n] | Code for systemic hormonal therapy[1-n]
+
Systemic therapies in the NCR are coded using the Anatomical Therapeutic Chemical (ATC) classification system. Recording of systemic therapy is not always specific; before 2015, non-specific codes were used more frequently.
|
||||||||||||||||||||||||||||
| Treatment data | horm_start_int[1-n] | Interval incidence date and start date of systemic hormonal therapy (days)[1-n] | ||||||||||||||||||||||||||||
| Treatment data | horm_startdat[1-n] | Start date of systemic hormonal therapy[1-n] | ||||||||||||||||||||||||||||
| Treatment data | horm_zkh[1-n] | Hospital where systemic hormonal therapy was administered[1-n] | ||||||||||||||||||||||||||||
| Treatment data | inv_rad_laatste | Radicality of the invasive component at last surgery
+
Available since 2011.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Treatment data | inv_rad1 | Radicality of the invasive component at initial surgery
+
Available since 2011.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Treatment data | meta_chir | Surgery targeting metastases performed |
valuelist
+
|
|||||||||||||||||||||||||||
| Treatment data | meta_rt | Radiotherapy targeting metastases performed |
valuelist
+
|
|||||||||||||||||||||||||||
| Treatment data | okd | Axillary lymph node dissection performed |
valuelist
+
|
|||||||||||||||||||||||||||
| Treatment data | okd_dat | Date of axillary lymph node dissection | ||||||||||||||||||||||||||||
| Treatment data | okd_int | Interval incidence date and date of axillary lymph node dissection (days)
+
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||
| Treatment data | okd_zkh | Hospital where axillary lymph node dissection was performed |
valuelist
+
|
|||||||||||||||||||||||||||
| Treatment data | residu | Residual tumour after all surgical procedures
+
Available until 2016
Indicates for invasive tumours, whether there is residual tumour after all surgical treatments.
0 = no tumour residue: If surgery is part of the initial treatment, the pathologist indicates that the resection margins are clear and/or that the procedure was radical, and the surgeon does not state in the operative report that possible residual tumour has been left behind. This also applies if, in addition to the primary tumour, a solitary distant metastasis has been removed.
1 = microscopic tumour residue: If surgery is part of the initial treatment, the pathologist indicates that the resection margins are not clear and/or that the procedure was not radical, and the surgeon does not state in the operative report that possible residual tumour has been left behind.
2 = macroscopic tumour residue: If surgery is part of the initial treatment and the surgeon states in the operative report that residual tumour has been left behind (the pathology report is not relevant for this code). This also applies if there are distant metastases or regional lymph node metastases that have not been removed.
Note: Tumour residue has a different meaning than radicality, which for some tumour types is recorded per surgical resection.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Treatment data | rt | Radiotherapy classified as pre- or post-surgical
+
This variable refers to radiotherapy targeting the primary tumour.
Determination of pre- and post-surgical therapy is based on the chronological order of procedures in the NCR. The first surgical resection is used as the reference point. Local procedures (e.g. tumour destruction, excision biopsy, photodynamic therapy, electrocautery, cryosurgery, radiofrequency ablation) are excluded from this determination.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Treatment data | rt_start_int | Interval between incidence date and start date of radiotherapy (days)
+
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||
| Treatment data | rt_stop_int | Interval between incidence date and end date of radiotherapy (days)
+
Available since 2011. The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||
| Treatment data | rt_startdat | Start date of radiotherapy | ||||||||||||||||||||||||||||
| Treatment data | rt_stopdat | End date of radiotherapy
+
Available since 2011.
|
||||||||||||||||||||||||||||
| Treatment data | rt_type | Type of external beam radiotherapy
+
Available from 2011. This variable includes external beam radiotherapy as well as intraoperative radiotherapy. This is a form of radiotherapy that is applied on a limited scale in the Netherlands and is delivered during surgery.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Treatment data | rt_zkh | Hospital where radiotherapy was performed |
valuelist
+
|
|||||||||||||||||||||||||||
| Treatment data | target | Systemic targeted therapy classified as pre- or post-surgical
+
This variable refers to systemic targeted therapy, including immunotherapy.
Determination of pre- and post-surgical therapy is based on the chronological order of procedures in the NCR. The first surgical resection is used as the reference point. Local procedures (e.g. tumour destruction, excision biopsy, photodynamic therapy, electrocautery, cryosurgery, radiofrequency ablation) are excluded from this determination.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Treatment data | target_code[1-n] | Code for systemic targeted therapy[1-n]
+
Systemic therapies in the NCR are coded using the Anatomical Therapeutic Chemical (ATC) classification system. Recording of systemic therapy is not always specific; before 2015, non-specific codes were used more frequently.
|
||||||||||||||||||||||||||||
| Treatment data | target_start_int[1-n] | Interval incidence date and start date of systemic targeted therapy (days)[1-n] | ||||||||||||||||||||||||||||
| Treatment data | target_stop_int[1-n] | Interval incidence date and stop date of systemic targeted therapy (days)[1-n] | ||||||||||||||||||||||||||||
| Treatment data | target_startdat [1-n] | Start date of systemic targeted therapy[1-n] | ||||||||||||||||||||||||||||
| Treatment data | target_stopdat[1-n] | Stop date of systemic targeted therapy[1-n] | ||||||||||||||||||||||||||||
| Treatment data | target_zkh[1-n] | Hospital where systemic targeted therapy was administered[1-n] | ||||||||||||||||||||||||||||
| Treatment data | uitgebr_chir_dat | Date of the most extensive surgical procedure | ||||||||||||||||||||||||||||
| Treatment data | uitgebr_chir_int | Interval between incidence date and date of the most extensive surgical procedure (days)
+
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||
| Treatment data | uitgebr_chir_type | Type of the most extensive surgical procedure
+
Amputation/ablation is considered the most extensive surgery, followed respectively by lumpectomy, incidental finding during surgery for another indication (as sole surgery), ALND as sole surgery for occult breast carcinoma (cT=0), and other surgery.
|
valuelist
+
|
|||||||||||||||||||||||||||
| Treatment data | uitgebr_chir_zkh | Hospital where the most extensive surgical procedure was performed |
valuelist
+
|